Cidara Therapeutics, Inc., a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, and Mundipharma announced...

Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the company has received a grant for up to $6.9 million from CARB-X (Combating...

Cidara Therapeutics, an antimicrobial development company out of San Diego, California, has recently reported positive Phase I results of a novel antifungal agent, CD101 IV. CD101 IV is a small molecule...